Conference on 7th Annual Pain Management

Conference on 7th Annual Pain Management
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK

Background Info

Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas

Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?

Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.

Learn, exchange ideas and acquire knowledge on:

• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies

Who should attend?

Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine

Day 1
7th Annual Pain Management
Monday 18th October 2010

09:30 Registration and refreshments.

10:00 Opening address from the chair.

Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford

10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.

Anastasia Liapi
Director, Business Development Astellas

10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.

Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University

11:30 Morning refreshments.

11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.

Iain Chessell
Vice President, Neuroscience MedImmune

12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.

Steve England
Associate Research Fellow Pfizer

13:10 Networking lunch.

14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.

Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University

14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.

Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford

15:30 Afternoon refreshments.

15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.

16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.

17:10 Closing remarks from the chair.

17:20 Networking drinks.

Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2
7th Annual Pain Management
Tuesday 19th October 2010

09:30 Registration and refreshments.

10:00 Opening address from the Chair.

Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer

10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.

Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson

10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.

Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester

11:30 Morning refreshments.

11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.

Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital

12:30 What is the impact of chromatin modifications on establishing chronic pain state?

• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.

Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford

13:10 Networking lunch.

14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.

Stephen Wright
Research and Development Director GW Pharmaceuticals

Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen

14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?

15:30 Afternoon refreshments.

15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.

Dic Williams
Research Fellow, Pain Therapeutics Pfizer

16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.

17:10 Chair’s closing remarks.

17:20 End of conference.

For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html

OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com